Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Clinical Cancer Research

Volumn 16, Issue 10, 2010, Pages 2872-2880

  Dickgreber, Nicolas J ^a   Sorensen, Jens Benn ^b   Paz Ares, Luis G ^c   Schytte, Tine Kjestrup ^d   Latz, Jane E ^e   Schneck, Karen B ^e   Yuan, Zheng ^e   Sanchez Torres, José Miguel ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b FINSEN LABORATORY   (Denmark)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e ELI LILLY AND COMPANY   (United States)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHOTREXATE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; ASTHENIA; BLOOD SAMPLING; BLOOD TOXICITY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INTERSTITIAL FLUID; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PERITONEUM MESOTHELIOMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASCITES; CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS;

EID: 77952388819     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3324     Document Type: Article

References (39)

1. Fenton KN, Richardson JD. Diagnosis and management of malignant pleural effusions. Am J Surg 1995;170:69-74.
2. Spira A, Brahmer J. Effusions. In: Abeloff M, Armitage J, Niederhuber J, et al, editors. Clinical oncology. Third ed. Philadelphia (PA): Elsevier Churchill Livingstone; 2004, p. 1179-1212
3. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974;34:3487-3491
4. Chabner BA, Stoller RG, Hande K, Jacobs S, Young RC. Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion. Drug Metab Rev 1978;8:107-117 (Pubitemid 9051925)
5. Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978;23:68-72.
6. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002;50:373-382 (Pubitemid 35440526)
7. Chabner BA, Young RC. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973;52:1804-1811
8. Methotrexate [package insert]. Bedford (OH): Ben Venue Laboratories, Inc.; 2009.
9. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551
10. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597 (Pubitemid 41079796)
12. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644 (Pubitemid 46606305)
13. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-1104
14. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44:372-380
15. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998;57:110-113 (Pubitemid 28177541)
16. Mita AC, Sweeney CJ, Baker SD, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 2006;24:552-562 (Pubitemid 46630417)
17. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A semimechanistic-physiologic population pharmacokinetic/ pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006;57:412-426 (Pubitemid 43087584)
18. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006;57:427-435 (Pubitemid 43087585)
19. Latz J, Claret L, Symanowski J, et al. Evaluation of pemetrexed (PEM) dosing paradigms using exposure-response relationships (ERRs). J Clin Oncol ASCO Annual Meeting Proceedings Part I 2007;25:abstract 2530.
20. Latz J, Adachi S, Symanowski J, et al. Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations: PD44-3-4. J Thorac Oncol 2007;2:S455-6.
21. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007;13:2675-2683
22. Cullen MH, Zatloukal P, Sörenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19:939-945 (Pubitemid 351627311)
23. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14:4206-4212
24. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655
25. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205 (Pubitemid 46638957)
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216
27. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.
28. Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-411 (Pubitemid 43087583)
29. Ludden TM. Population pharmacokinetics. J Clin Pharmacol 1988;28:1059-1063
30. Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development. Ann Rev Pharmacol Toxicol 2000;40:67-95.
31. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM user's guide. Ellicott City (MD): Icon Development Solutions; 1989-2006.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
33. ALIMTA® pemetrexed for injections (USA package insert). Indianapolis (IN): Eli Lilly and Company; 2009.
34. Brandes JC, Grossman SA, Ahmad H. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest 2006;24:283-287
35. Sekine I, Sumi M, Saijo N. Local control of regional and metastatic lesions and indication for systemic chemotherapy in patients with non-small cell lung cancer. Oncologist 2008;13:21-27
36. Specenier PM, Ciuleanu T, Latz JE, Musib LC, Darstein CL, Vermorken JB. Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Cancer Chemother Pharmacol 2009;64:233-241
37. Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer. Clin Cancer Res 2009;15:382-389
38. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-373 (Pubitemid 32816541)
39. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276-80s.